HMINERS LAUNCH THE MOST POWERFUL CRYPTOCURRENCY MINING RIGS WITH UNIQUE FEATURES

Hminers has just introduced three new mining rigs with extraordinary features. The company already has the unique distinction of delivering the first ever 10nm ASIC mining rig in the cryptocurrency market.

MIAMI, Aug 16 (Bernama-GLOBE NEWSWIRE) -- Hminers is delighted to announce the mega launch of three new products that will make cryptocurrency mining easy and efficient like never before. This Miami-based organization is one of the most trusted names in the cryptocurrency market with the distinction of creating the world's first 10 nm ASIC Chip. The company's three new products H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U are now up for sale at www.Hminers.com.

As the difficulties in bitcoin mining have kept on increasing over the last few years, Hminers has embraced new principles to create multi algorithm based miners. Each of the three new products from the company is built and designed to operate under multiple algorithms and provide customers the freedom to switch to any coin that offers them a better income. In addition to bitcoin, these products can be used to mine Litecoin, Ethereum, and Dash.

http://mrem.bernama.com/viewsm.php?idm=29818

VISTAJET HARNESSES THE POWER OF THE AMERICAN ECLIPSE TO OFFER CUSTOMERS A RARE VIEWING OPPORTUNITY

VistaJet invites customers to fly in parallel with an astronomical anomaly

NEW YORK, Aug 16 (Bernama-GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, will be offering customers the opportunity to experience and chase the American Solar Eclipse, appearing for the first time in 99 years on August 21, 2017.

http://mrem.bernama.com/viewsm.php?idm=29817

HOULIHAN LOKEY ADDS MANAGING DIRECTOR TO ITS SYDNEY OFFICE

Matthew Tehan Joins to Lead Firm’s Capital Markets Business in Australia

SYDNEY, AUSTRALIA, Aug 15 (Bernama-GLOBE NEWSWIRE) -- Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced that Matthew Tehan has joined the Capital Markets Group as a Managing Director. He is based in Sydney and will lead the firm’s Capital Markets efforts in Australia.

Mr. Tehan joins Houlihan Lokey following a 17-year career at Credit Suisse, where he held a number of roles, including serving as Co-Head of Debt and Derivatives in the firm’s Capital Markets Solutions Group in Sydney. During that time, he led the structuring and origination of numerous capital markets transactions for corporate clients, including acquisition debt, mezzanine debt, and both capital markets distribution and on-balance-sheet transactions. His prior experience also includes working in Credit Suisse’s Global Markets Solutions Group and for Credit Suisse Financial Products in New York. Mr. Tehan began his career at EY in 1995.

“Matthew’s breadth of experience across the full spectrum of debt financing, combined with his expertise in risk management and strong client relationships across the region, makes him an excellent addition to our successful global Capital Markets team,” said Scott Adelson, Co-President of Houlihan Lokey. “The firm’s longtime focus on non-traditional sources of capital and the solutions they can provide reflects our client-centric culture and commitment to delivering exceptional outcomes. Matthew’s deep commitment to client service represents an exceptional fit with our culture and client needs in the market.”

“I’m excited to join one of the financial services industry’s largest and most active independent private financing teams,” said Mr. Tehan. “The group’s track record of success is outstanding, and I hope to continue that track record as we expand Houlihan Lokey’s Capital Markets capabilities in Australia,” he added.
Mr. Tehan holds a B.Com. in Finance and Accounting and a B.A. in Politics and English Literature from the University of Melbourne. He is also a member of the Institute of Chartered Accountants of Australia (CA).

With 35 professionals globally, Houlihan Lokey’s Capital Markets Group is focused on delivering its clients bespoke financing solutions backed by superior market knowledge and execution capabilities. Over the past 12 months, the group has raised nearly $6 billion for clients across more than 30 transactions. The group has added a total of three Managing Directors over the past seven months in Sydney, New York, and London. 

http://mrem.bernama.com/viewsm.php?idm=29806

TACONIC BIOSCIENCES ANNOUNCES PARTNERSHIP WITH CERGENTIS B.V. TO PROVIDE TRANSGENE MAPPING SERVICES

HUDSON, N.Y., Aug 15 (Bernama-GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement with Cergentis B.V. (“Cergentis”) to leverage the company’s Targeted Locus Amplification (TLA) technology to provide transgene mapping services to its customers.

While transgenic mice generated via random pro-nuclear injection (PNI) continue to be a critical tool in biomedical research, a distinct disadvantage of these models is the inability to direct the transgene to a specific integration site within the genome. Cergentis has developed a next generation sequencing method based on their patented TLA technology. Taconic’s Transgene Mapping Analysis (TgMA)service leverages this platform, making the task of determining the precise location of a randomly inserted transgene much easier. In addition to the sequencing data from Cergentis, Taconic provides expert interpretation specific to the transgenic line, leading to an optimized breeding strategy.

“Cergentis TLA technology brings characterization of transgenic rodent models to a whole new level. This technology enables quick and reliable determination of transgene insertion site(s) while providing important data regarding the integrity of the transgene itself and potential disruption of endogenous genes. Taconic can now provide precise assessment of a transgenic model and use the TLA data to better plan intercrosses for future studies,” shared Dr. Jochen Welcker, director of molecular biology and scientific development.

Cergentis CEO Max van Min comments: “Cergentis is delighted with this collaboration. Taconic is a leading supplier of rodent models and by leveraging both our expertise our common customers are served most effectively.”

Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience. The company provides gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR-Cas9, pronuclear injection, and homologous recombination technologies to ensure that the right tools are leveraged for each specific customer project. Taconic’s unique capability of providing a seamless transition from model design to breeding and colony management, offers customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.

Cergentis is based in the Netherlands and provides services and kits based on its proprietary Targeted Locus Amplification Technology. Uniquely, TLA enables targeted complete Next Generation Sequencing and the detection of all Single Nucleotide Variants and structural changes. Key applications of TLA include genetic diagnostics, oncogenetics, and sequencing of gene-editing events, transgenes and integration sites in amongst others plants, cells and animal models. Cergentis works for leading pharmaceutical companies and research institutes worldwide.

For more information contact info@cergentis.com.   

To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email info@taconic.com.  

About Taconic Biosciences, Inc. 

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.  Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Source : Taconic Biosciences

--BERNAMA

7 ENTRY CATEGORIES TO BE OFFERED IN 12TH GATSBY CREATIVE AWARDS, ASIA'S BIGGEST CREATIVE FESTIVAL FOR STUDENTS

OSAKA, Japan, Aug. 14, 2017 /Kyodo JBN-AsiaNet/ --

- Special Creative Festival for Students, Held across 11 Asian Countries &
  Regions -

Mandom Corporation based in Osaka, Japan, announced on August 14 the holding of the 12th GATSBY CREATIVE AWARDS in 11 countries and regions across Asia. GATSBY is the men's grooming brand from Mandom Corporation.

http://mrem.bernama.com/viewsm.php?idm=29801

BUTTE ENERGY INC. ANNOUNCES RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS AND CHANGES TO MANAGEMENT

CALGARY, Alberta, Aug 14 (Bernama-GLOBE NEWSWIRE) -- Butte Energy Inc. (“Butte” or the “Company”) is pleased to announce the results of its Annual General and Special Meeting of shareholders held on August 1, 2017 in Calgary (the “Meeting”). At the Meeting, shareholders holding 77.42% of the issued and outstanding common shares were present or represented by proxy and such shareholders voted 100% in favour of the sale of the Company’s Chigwell properties to RKSmith Energy Corp. for $35,000 (the “Transaction”).

In addition, the Company is pleased to announce the re-election of Charles Baker, Chris Reimchen, Victor Redekop, Gerald Gilbert and Cuneyt Tirmandi. At the Meeting shareholders also re-appointed Czechowsky, Graham & Hanevelt Chartered Accountants as auditors of the Company and approved a special resolution approving the winding up of the Company, the full text of which is set forth in the Company’s management information circular dated June 30, 2017.

http://mrem.bernama.com/viewsm.php?idm=29799

RedHill Biopharma Provides 2017 Semi-Annual Business Update

- RedHill’s U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill’s late clinical-stage GI products, if approved, and for the acquisition of additional commercial GI products

- The ERADICATE Hp2 confirmatory Phase III study with TALICIA™ (RHB-105) for H. pylori bacterial infection is ongoing; TALICIA™ was granted QIDP designation by the FDA

- Following a unanimous positive DSMB recommendation, the Phase III MAP US study with RHB-104 for Crohn’s disease is continuing as planned; An open-label extension Phase III study (the MAP US2 study) is ongoing in parallel

- Following positive top-line results from the Phase III study with BEKINDA® 24 mg for acute gastroenteritis, the outcome of the planned FDA Type B meeting to discuss the potential path to marketing approval is expected to be announced in October 2017

- Top-line results from the Phase II study with BEKINDA® 12 mg for diarrhea-predominant irritable bowel syndrome (IBS-D) are expected in September 2017

- In light of recent FDA guidance on the potential path to marketing approval of RHB-104 as first-line therapy for nontuberculous mycobacteria (NTM) infections, RedHill plans, subject to regulatory approvals, to initiate a pivotal Phase III study in the U.S. with RHB-104 for NTM infections in the first quarter of 2018; RHB-104 was granted QIDP designation by the FDA for the treatment of NTM infections

- In light of encouraging results from prior non-clinical studies, an NIAID Safety Committee recently approved a planned proof-of-concept study to evaluate RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease; The study is expected to be initiated in the fourth quarter of 2017

- Re-submission of the NDA for RIZAPORT® for acute migraines is expected in October 2017

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 11 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today provided an update on key programs, potential milestones and estimated timelines.

Dror Ben-Asher, Chief Executive Officer of RedHill, said: “RedHill has transitioned into a revenue-generating, gastrointestinal-focused, specialty pharmaceutical company, as we continue to pursue important clinical development milestones in the near future. I would like to thank the RedHill team for their meaningful achievements on the R&D and commercial fronts thus far in 2017.”

Source : RedHill Biopharma Ltd.